Prevail Clinical Research in Liberia

Prevail Clinical Research in Liberia PREVAIL is a Joint Clinical Research project between the Liberian and US governments, represented by Thank you for taking the time to review our comment policy.

PREVAIL Social Media Comment and Disclaimer Policy

The PREVAIL page is to encourage public understanding of our research messages and participation in the discussion of health-related information. Our core values encompass respect and tolerance of diverse people, cultures, and ideas and subscribe to the principles of Good Participatory Practices. To fulfill these values, we have posted t

he PREVAIL Social Media comment policy below for your reference. While we encourage followers to actively engage with our content and discussion points, we expect that this will be done in a very respectful manner. PREVAIL does not authorize or endorse every comment posted on our page. Comments from individual followers should be regarded as opinions shared and not necessarily facts. Our goal is to share information with as many people as possible; hence, we will accept people sharing our posts or tagging others in their comments. All opinions are welcome, but comments should be respectful and relevant to PREVAIL. The following is prohibited:
• Personal attacks, profanity, and aggressive behavior
• Instigating arguments in a disrespectful way
• Spreading misleading or false information
• Repeated posting of identical or very similar content in a negative manner

Comments will be deleted if they contain:
• Profanity, indecency, or vulgarity,
• Nudity
• Defamation to a person or people
• Name-calling and/or personal attacks
• Spams
• Political views
• Commercial endorsements
• Discriminatory, racist, offensive, indecent, inflammatory, unlawful language or content

PREVAIL retains the right to determine which comments violate this comment policy. We also reserve the right to remove and/or not allow comments to get posted. Any follower who violates this policy may be blocked from the PREVAIL social media profiles. We understand that social media is a 24/7 communication platform; however, our capacity to moderate the platform is not. We may not see every inappropriate comment right away, and we are trusting in the maturity of our community/stakeholders to ignore personal attacks and negative speech or respond politely. We encourage your participation in all discussions and look forward to an interactive exchange of ideas. Disclaimer

Posted comments and images do not necessarily represent the views of PREVAIL. External links on this site do not constitute official endorsement on behalf of PREVAIL. PREVAIL is a Joint Clinical Research project between the Liberian and US governments, represented by the Liberian Ministry of Health (MOH), and the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID), respectively. However, contents shared through this platform do not represent the NIH or the Federal government of the United States of America; neither does it represent the Liberian Ministry of Health, and all other partners.

30/12/2024

SMC disseminates Neuro Sub study results to internal staff # #

The SMC Department of Prevail has distributed the Neuro Substudy to internal staff, starting at the Redemption Prevail Site. Sharing updates on study findings with internal Prevail staff will help them gain a better understanding of the outcomes from the various studies they are conducting within Prevail.

International research consortium tackles Lassa vaccine development from concept to clinic. Dr. Mark Kieh presented the ...
22/11/2024

International research consortium tackles Lassa vaccine development from concept to clinic. Dr. Mark Kieh presented the results of a CEPI supported study conducted across both the United States and Liberia.

Lassa virus (LASV) is a zoonotic viral hemorrhagic fever endemic to West Africa and classified as a priority pathogen by the World Health Organization (WHO). It causes an estimated 5,000 deaths and 300,000 illnesses annually, though the true burden is likely higher. An urgent need exists for a vaccine, as modeling studies suggest that a LASV vaccine could save thousands of lives and prevent up to US$128 million in societal costs over the next decade. With LASV’s geographic spread expanding due to climate change, urbanization, and other factors, vaccine development efforts are intensifying. The Coalition for Epidemic Preparedness Innovations (CEPI) is the leading funder of LASV vaccine research, supporting six candidates, four of which are in clinical trials. Among these, IAVI’s vesicular stomatitis virus (VSV)-based LASV vaccine is the furthest along. Leveraging the proven VSV platform used in Merck’s Ebola vaccine (Ervebo®), IAVI and its partners are advancing accessible vaccines for LASV and other priority diseases. At the recent TropMed conference, researchers shared updates on preclinical studies and Phase 1 clinical trial results for LASV vaccine candidates.

Dr. Mark Kieh, the principal investigator of the IAVI-sponsored Phase 1 clinical trial of IAVI's Lassa fever vaccine candidate at PREVAIL in Liberia, presented the results of a CEPI-supported study conducted across both the United States and Liberia.
The trial investigated the safety and immunogenicity of the vaccine candidate in two distinct cohorts. The findings demonstrated that the vaccine was well tolerated by participants in both locations. Additionally, the vaccine induced robust immune responses in both groups, with no safety concerns or adverse events identified throughout the trial.

These encouraging results provide critical evidence for the continued development of the vaccine, supporting its progression into Phase 2 clinical testing. The Phase 2 trials will further assess the candidate's efficacy, safety, and long-term immune responses in a larger population, moving closer to a potential solution for combating Lassa fever.
https://iamtropmed.org/blog/2024/11/18/international-research-consortium-tackles-lassa-vaccine-development-from-concept-to-clinic

12/11/2024

Lassa Fever affects thousands of people annually, particularly in West Africa, and can lead to severe health complications. A successful vaccine could save countless lives and help control outbreaks. The PREVAIL Social Mobilization Team provided education on the enrollment processes in the Sinkor communities.

Prevail is currently conducting a Lassa Fever Vaccine Study at the JFK Prevail Site.

05/11/2024

What Is the Importance of Conducting Biomedical Research on Infectious Diseases in the Community?

04/11/2024

# # What are Your thoughts on the infectious disease vaccine trial in your country?
How can we better support research initiatives in our communities?
Share your questions and insights below!

Join the conversation on vaccines trail during an infectious disease outbreak!

31/10/2024

Good morning to all our valued followers! We truly appreciate your support and opinions on our posts. Please don’t hesitate to reach out if you need further clarification or wish to engage with us regarding any content shared on our page.

As a vibrant research institution, Prevail is committed to conducting high-quality clinical and observational research in Liberia. Our headquarters is located at the AMD Dogliotti College of Medicine, next to St. Joseph Catholic Hospital.

We look forward to your continued engagement!

Call now to connect with business.

Address

Congo Town
Monrovia
1000

Opening Hours

Monday 08:00 - 17:00
Tuesday 08:00 - 17:00
Wednesday 08:00 - 17:00
Thursday 08:00 - 17:00
Friday 08:00 - 17:00

Website

Alerts

Be the first to know and let us send you an email when Prevail Clinical Research in Liberia posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category